Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1636 1651 1657 1658
This examiner grants 100% of resolved cases
Caroline Monserrat Lara has a data set of 4 resolved cases in Tech Center 1600 and Art Unit 1633. The allowance rate pct is 100.0, and the median days to allowance is 1234. These figures indicate the path for the few cases resolved so far. The 1234-day median to allowance is a metric for applicants to consider when planning their strategy in Art Unit 1633. With these resolved cases, the statistics are early indicators of her performance.
The interview lift pct of 0.0 suggests that interviews have not yet impacted the allowance probability for this examiner. This 0.0 lift is consistent with the 100.0 allowance rate pct already recorded. Practitioners should watch for more data to confirm if these trends are representative of her long-term prosecution style. The 1234-day median suggests that while success is recorded in the 4 cases, applicants should be prepared for the duration of the process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18706176 | AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH’S ATAXIA | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | Final Rejection | ModernaTX, Inc. |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | Final Rejection | ModernaTX, Inc. |
| 18440260 | EFFICIENT DIFFERENTIATION OF SECOND HEART FIELD CARDIAC PROGENITOR CELLS AND RIGHT VENTRICLE CARDIOMYOCYTES FROM HUMAN PLURIPOTENT STEM CELLS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18555508 | PACKAGING CELLS WITH TARGETED GENE KNOCKOUTS THAT IMPROVE RETROVIRAL VECTOR TITERS | Non-Final OA | The Regents of the University of California |
| 18763564 | HIGH-EFFICIENCY EXPRESSION VECTOR OF CIRCULAR RIBONUCLEIC ACID (circRNA) AND USE THEREOF | Non-Final OA | Zhejiang University |
| 18528348 | GENERATING QUIESCENT HEPATIC STELLATE CELLS AND THEIR USE IN LIVER MODELS | Non-Final OA | The Cleveland Clinic Foundation |
| 18549887 | SYSTEMS, METHODS, AND COMPOSITIONS FOR ALTERING THE EXPRESSION OF ENDOGENOUS CIRCULAR RNAS | Non-Final OA | UNM Rainforest Innovations |
| 18184568 | PERSISTENT HSV GENE DELIVERY SYSTEM | Non-Final OA | University of Houston System |
| 18626156 | MODIFIED REP-CAP PLASMIDS AND USES THEREOF | Non-Final OA | Decibel Therapeutics, Inc. |
| 18841883 | ENGINEERED IMMUNOMODULATORY ACCESSORY CELLS IMPROVE ALLOGENEIC ISLET TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION | Non-Final OA | CORNELL UNIVERSITY |
| 18842179 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18555584 | CULTURE OF TUMOR INFILTRATING LYMPHOCYTES FROM TUMOR DIGEST | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18775133 | Creation of Inducible Pluripotent Stem Cell Derived T Regulatory Cells by In Vitro Recapitulation ofThymic Development | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18696121 | METHOD FOR PRODUCING CELL HAVING DNA DELETION SPECIFIC TO ONE OF HOMOLOGOUS CHROMOSOMES | Non-Final OA | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy